Archive — US — turtlesai
New Multi-omic Blood Test Identifies Over 20 Cancers Early
SeekInCare, developed by SeekIn Inc., is a multi-omic blood test for the early diagnosis of over 20 cancers, integrating genomic and proteomic data with AI. With a sensitivity of 72.2% and specificity of 96.1% in a real-world cohort, it signifies a significant advancement in early cancer detection, enhancing patient outcomes through non-invasive methods.
Key points
- Developed by SeekIn Inc., SeekInCare tests for over 20 types of cancer using multi-omics technology.
- The test analyzes circulating cell-free DNA (cfDNA) and seven protein tumor markers from a single blood draw.
- Employs a cancer risk model (CRS Algorithm) to ascertain cancer presence and origin.
- Clinical validation achieved sensitivity of 69.4% and specificity of 98.0% in retrospective studies involving 1,800 individuals.
- In prospective cohorts of 1,212 subjects, sensitivity increased to 72.2% and specificity to 96.1%.
- Sensitivity varies by stage: 50.3% (stage I), 64.0% (stage II), 73.8% (stage III), and 86.2% (stage IV).
- Earned the CE-IVD mark in November 2021, confirming compliance with European diagnostic standards.
Why it matters
- In 2025, advanced diagnostic tools are integral to improving early cancer detection rates.
- The increasing use of AI in healthcare reflects broader digital transformation trends across medical diagnostics.
- SeekInCare aligns with the growing emphasis on personalized medicine and non-invasive testing methods.
SeekInCare offers a pioneering approach to early cancer detection, using integrated data and AI, promising better patient outcomes and indicating a shift toward more effective diagnostic technologies in healthcare.